Blackrock Microsystems Obtains Expanded 510(k) to Market NeuroP...( Blackrock's ...)

Blackrock's NeuroPort Biopotential Neural Signal Processing System enables acute monitoring, signal detection and analysis to facilitate development of new clinical therapies with the potential to improve diagnosis and treatment of a wide range of brain disorders including Epilepsy and Parkinson's disease. The NeuroPort System is uniquely capable of monitoring from as many as 256 channels, with the potential to be scalable to more than a thousand channels (in increments of 256 channels), to improve intracranial high-channel direct recording of brain activity.The enhanced NeuroPort System offers physicians and neuroscience researchers richer data related to spatial and temporal resolution at the level of single neurons.

Salt Lake City, Utah (PRWEB) July 15, 2009 -- Blackrock Microsystems LLC today announced that it has received a new, expanded 510(k) marketing approval from the U.S. Food and Drug Administration. The new labeling allows the NeuroPort Biopotential Neural Signal Processor (NeuroPort System) to be used with electrodes supplied by users, as well as with the implantable NeuroPort Cortical Microelectrode Array (NeuroPort Array) covered by a previous 510(k). In addition, the new 510(k) for the NeuroPort System has been expanded to include its use in medical applications beyond brain monitoring.

The biopotential signals that the NeuroPort System is designed to detect, record and analyze include electrocorticography (ECoG), electroencephalography (EEG), electromyography (EMG), electrocardiography (ECG), electrooculography (EOG) and Evoked Potential (EP).
The NeuroPort System provides neuroscientists, neur
'/>"/>